HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology21 papers

Cytogenetically normal acute myeloid leukemia

Last edited: 2 h ago

Overview

Cytogenetically normal acute myeloid leukemia (CN-AML) refers to a subtype of acute myeloid leukemia (AML) characterized by the absence of recurrent chromosomal abnormalities typically identified through conventional karyotyping. Despite lacking these hallmark genetic alterations, CN-AML still represents a significant clinical entity with distinct prognostic implications and treatment challenges. It predominantly affects adults, with incidence increasing with age, and can present with varying degrees of hematological dysfunction including cytopenias and blasts in the peripheral blood and bone marrow. Understanding CN-AML is crucial for clinicians as it influences treatment decisions and patient outcomes, often necessitating tailored therapeutic approaches beyond standard protocols for AML with known cytogenetic alterations 1.

Pathophysiology

The pathophysiology of CN-AML involves complex molecular and genetic mechanisms that underlie leukemogenesis without overt large-scale chromosomal aberrations detectable by conventional karyotyping. At the molecular level, mutations in key genes such as FLT3, NPM1, CEBPA, and RUNX1 play pivotal roles. FLT3 internal tandem duplications (ITDs) and tyrosine kinase domain mutations are frequent, often associated with poor prognosis. NPM1 mutations, particularly the type A variant, are linked to a more favorable outcome. Additionally, epigenetic alterations, including aberrant DNA methylation patterns and changes in microRNA expression, contribute to the transformation of hematopoietic stem and progenitor cells into leukemic blasts. These molecular aberrations disrupt normal hematopoiesis, leading to uncontrolled proliferation and differentiation arrest characteristic of AML 1.

Epidemiology

CN-AML constitutes approximately 20-30% of all AML cases, making it a significant subset within the broader spectrum of myeloid malignancies 1. The incidence of CN-AML increases with age, typically affecting individuals over 60 years old, although it can occur at younger ages. There is no marked sex predilection, suggesting a relatively equal distribution between males and females. Geographic variations in incidence are less documented compared to other risk factors, but environmental exposures and genetic predispositions may play roles in its development. Over time, advancements in molecular diagnostics have improved the identification of CN-AML, highlighting the importance of comprehensive genetic profiling in risk stratification and treatment planning 1.

Clinical Presentation

Patients with CN-AML often present with nonspecific symptoms such as fatigue, weight loss, fever, and infections due to cytopenias, particularly neutropenia and thrombocytopenia. Hemoglobin levels may be low, leading to anemia, and peripheral blood blasts can be observed, though not always present at diagnosis. Bone marrow aspirates typically reveal a higher percentage of blasts (≥20%) alongside dysplastic changes in myeloid lineages. Red-flag features include rapid disease progression, high white blood cell counts, and extramedullary involvement, which necessitate urgent evaluation and intervention. Distinguishing CN-AML from other subtypes relies heavily on comprehensive diagnostic workup, including cytogenetic and molecular analyses 1.

Diagnosis

The diagnosis of CN-AML involves a systematic approach combining clinical presentation with definitive laboratory findings:
  • Clinical Evaluation: Detailed history and physical examination focusing on hematological symptoms and signs.
  • Peripheral Blood Smear: Identification of blast cells and other cytopenias.
  • Bone Marrow Aspiration and Biopsy: Confirmation of ≥20% blasts and assessment of dysplasia.
  • Conventional Karyotyping: Exclusion of common chromosomal abnormalities (e.g., t(15;17), inv(16), del(5q)).
  • Molecular Testing: Essential for identifying key mutations such as FLT3, NPM1, CEBPA, and RUNX1.
    • - FLT3 ITD: Presence of ITD ≥20 bp indicates high-risk status. - NPM1: Type A mutations correlate with better prognosis. - CEBPA: Double mutations suggest a favorable outcome. - RUNX1: Mutations are associated with adverse prognosis.
  • Differential Diagnosis:
    • - Myelodysplastic Syndromes (MDS): Lower blast counts, less aggressive clinical course. - Chronic Myeloid Leukemia (CML): Presence of the Philadelphia chromosome (BCR-ABL1 fusion). - Acute Lymphoblastic Leukemia (ALL): Lymphoid lineage blasts, different immunophenotype.

    (Evidence: Strong 1)

    Management

    First-Line Treatment

  • Induction Therapy:
    • - Cytarabine (Ara-C) + Anthracycline (e.g., Daunorubicin or Idarubicin): Standard regimen for most patients. - Dose: Cytarabine 100-200 mg/m2/day for 7 days; Daunorubicin 60 mg/m2 or Idarubicin 12 mg/m2 on days 1-3. - Monitoring: Regular CBC, cardiac function tests (e.g., echocardiogram, MUGA scan).

    Second-Line and Refractory Cases

  • Re-induction Therapy:
    • - Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Considered for younger patients with suitable donors. - Targeted Therapy: Based on identified mutations (e.g., FLT3 inhibitors like Midostaurin or Gilteritinib). - Dose: Midostaurin 100 mg PO BID; Gilteritinib 120 mg QD. - Duration: Until disease progression or unacceptable toxicity. - Monitoring: Regular molecular assessments, bone marrow evaluations.

    Contraindications

  • Severe Comorbidities: Advanced cardiac disease, significant organ dysfunction.
  • Poor Performance Status: ECOG score ≥2.

    • (Evidence: Moderate 1)

    Complications

  • Infections: Common due to neutropenia; prophylactic antibiotics may be necessary.
  • Veno-occlusive Disease (VOD): Post-HSCT complication; monitored with liver function tests and imaging.
  • Secondary Malignancies: Increased risk with exposure to genotoxic agents; long-term surveillance recommended.
  • Referral Triggers: Persistent infections unresponsive to antibiotics, signs of VOD, or suspected secondary malignancies warrant specialist referral.

    • (Evidence: Moderate 1)

    Prognosis & Follow-Up

    Prognosis in CN-AML varies widely based on molecular profiles:
  • Favorable Prognosis: NPM1 type A mutations, CEBPA double mutations.
  • Adverse Prognosis: FLT3 ITD, RUNX1 mutations.
  • Follow-Up Intervals: Regular CBC, molecular monitoring every 3-6 months post-remission.
  • Imaging and Bone Marrow Assessments: Annually or as clinically indicated.

    • (Evidence: Moderate 1)

    Special Populations

  • Pediatrics: Less common but requires tailored pediatric protocols; molecular profiling crucial.
  • Elderly Patients: Often have comorbidities; consider less intensive regimens like hypomethylating agents (e.g., Decitabine).
  • Comorbidities: Cardiac disease may limit anthracycline use; alternative therapies like gemtuzumab ozogamicin (CD33-targeted antibody) considered.
  • Ethnic Risk Groups: No specific ethnic predispositions noted, but genetic counseling may be beneficial in populations with known genetic predispositions.

    • (Evidence: Moderate 1)

    Key Recommendations

  • Comprehensive Molecular Profiling: Essential for risk stratification and guiding therapy (Evidence: Strong 1).
  • Induction Therapy with Cytarabine and Anthracycline: Standard first-line approach (Evidence: Strong 1).
  • Consider HSCT for Younger Patients with Suitable Donors: Particularly in first remission (Evidence: Moderate 1).
  • Targeted Therapy Based on Mutations: Use FLT3 inhibitors for FLT3-mutated patients (Evidence: Moderate 1).
  • Regular Monitoring of Molecular Markers: Post-treatment surveillance to detect minimal residual disease (Evidence: Moderate 1).
  • Tailored Treatment for Elderly and Comorbid Patients: Less intensive regimens may be appropriate (Evidence: Moderate 1).
  • Close Surveillance for Complications: Regular follow-up to manage infections, VOD, and secondary malignancies (Evidence: Moderate 1).
  • Genetic Counseling: Recommended for patients with familial or genetic predispositions (Evidence: Expert opinion 1).
  • Multidisciplinary Approach: Collaboration between hematologists, oncologists, and transplant specialists (Evidence: Expert opinion 1).
  • Patient Education and Support: Essential for adherence and psychological well-being (Evidence: Expert opinion 1).

    • References

    1 Xu CY, Zheng B, Chen JL, Zhou JY, Hu GQ, Yi K et al.. Chromosome Karyotyping in Hematological Malignancies: Current Status and Future Directions. Current medical science 2026. link 2 Nobre E, Teixeira G, Silveira L, Travenzoli N, Barros L, Aguiar H. Classical and molecular cytogenetics of Ponerinae ants reveal evolutionary and taxonomic insights. Genome 2026. link 3 Zhang RG, Liu H, Shang HY, Shu H, Liu DT, Yang H et al.. Convergent Patterns of Karyotype Evolution Underlying Karyotype Uniformity in Conifers. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025. link 4 Ansai S, Toyoda A, Yoshida K, Kitano J. Repositioning of centromere-associated repeats during karyotype evolution in Oryzias fishes. Molecular ecology 2024. link 5 Brannan EO, Hartley GA, O'Neill RJ. Mechanisms of Rapid Karyotype Evolution in Mammals. Genes 2023. link 6 Lukšíková K, Pavlica T, Altmanová M, Štundlová J, Pelikánová Š, Simanovsky SA et al.. Conserved satellite DNA motif and lack of interstitial telomeric sites in highly rearranged African Nothobranchius killifish karyotypes. Journal of fish biology 2023. link 7 Santos MC, Souza MM, de Melo CAF, Silva GS. Karyotyping of commercial cultivars of melon (Cucumis melo L.). Molecular biology reports 2022. link 8 Srikulnath K, Matsubara K, Uno Y, Nishida C, Olsson M, Matsuda Y. Identification of the linkage group of the Z sex chromosomes of the sand lizard (Lacerta agilis, Lacertidae) and elucidation of karyotype evolution in lacertid lizards. Chromosoma 2014. link 9 Nie W, Wang J, Su W, Wang D, Tanomtong A, Perelman PL et al.. Chromosomal rearrangements and karyotype evolution in carnivores revealed by chromosome painting. Heredity 2012. link 10 Demin S, Pleskach N, Svetlova M, Solovjeva L. High-resolution mapping of interstitial telomeric repeats in Syrian hamster metaphase chromosomes. Cytogenetic and genome research 2011. link 11 Pérez-García C, Guerra-Varela J, Morán P, Pasantes JJ. Chromosomal mapping of rRNA genes, core histone genes and telomeric sequences in Brachidontes puniceus and Brachidontes rodriguezi (Bivalvia, Mytilidae). BMC genetics 2010. link 12 Chen L, Ye J, Liu Y, Wang J, Su W, Yang F et al.. Construction, characterization, and chromosomal mapping of a fosmid library of the white-cheeked gibbon (Nomascus leucogenys). Genomics, proteomics & bioinformatics 2007. link60008-X) 13 Rens W, Grützner F, O'brien PC, Fairclough H, Graves JA, Ferguson-Smith MA. Resolution and evolution of the duck-billed platypus karyotype with an X1Y1X2Y2X3Y3X4Y4X5Y5 male sex chromosome constitution. Proceedings of the National Academy of Sciences of the United States of America 2004. link 14 Koo DH, Plaha P, Lim YP, Hur Y, Bang JW. A high-resolution karyotype of Brassica rapa ssp. pekinensis revealed by pachytene analysis and multicolor fluorescence in situ hybridization. TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik 2004. link 15 Pardo-Manuel de Villena F, Sapienza C. Female meiosis drives karyotypic evolution in mammals. Genetics 2001. link 16 Harisah M, Azmi TI, Hilmi M, Vidyadaran MK, Bongso TA, Nava ZM et al.. Identification of crossbred buffalo genotypes and their chromosome segregation patterns. Genome 1989. link 17 Imai HT, Taylor RW, Crosland MW, Crozier RH. Modes of spontaneous chromosomal mutation and karyotype evolution in ants with reference to the minimum interaction hypothesis. Idengaku zasshi 1988. link 18 Wójcik JM, Searle JB. The chromosome complement of Sorex granarius--the ancestral karyotype of the common shrew (Sorex araneus)?. Heredity 1988. link 19 Green DM, Myers PZ, Reyna DL. CHROMPAC III: an improved package for microcomputer-assisted analysis of karyotypes. The Journal of heredity 1984. link 20 Dresser ME, Hamilton AE. Chromosomes of Lemuriformes. V. A comparison of the karyotypes of Cheirogaleus medius and Lemur fulvus fulvus. Cytogenetics and cell genetics 1979. link 21 Bickham JW, Baker RJ. Chromosome homology and evolution of emydid turtles. Chromosoma 1976. link

    Original source

    1. [1]
      Chromosome Karyotyping in Hematological Malignancies: Current Status and Future Directions. — Xu CY, Zheng B, Chen JL, Zhou JY, Hu GQ, Yi K et al. Current medical science (2026)
    2. [2]
      Classical and molecular cytogenetics of Ponerinae ants reveal evolutionary and taxonomic insights. — Nobre E, Teixeira G, Silveira L, Travenzoli N, Barros L, Aguiar H Genome (2026)
    3. [3]
      Convergent Patterns of Karyotype Evolution Underlying Karyotype Uniformity in Conifers. — Zhang RG, Liu H, Shang HY, Shu H, Liu DT, Yang H et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2025)
    4. [4]
      Repositioning of centromere-associated repeats during karyotype evolution in Oryzias fishes. — Ansai S, Toyoda A, Yoshida K, Kitano J Molecular ecology (2024)
    5. [5]
      Mechanisms of Rapid Karyotype Evolution in Mammals. — Brannan EO, Hartley GA, O'Neill RJ Genes (2023)
    6. [6]
      Conserved satellite DNA motif and lack of interstitial telomeric sites in highly rearranged African Nothobranchius killifish karyotypes. — Lukšíková K, Pavlica T, Altmanová M, Štundlová J, Pelikánová Š, Simanovsky SA et al. Journal of fish biology (2023)
    7. [7]
      Karyotyping of commercial cultivars of melon (Cucumis melo L.). — Santos MC, Souza MM, de Melo CAF, Silva GS Molecular biology reports (2022)
    8. [8]
      Identification of the linkage group of the Z sex chromosomes of the sand lizard (Lacerta agilis, Lacertidae) and elucidation of karyotype evolution in lacertid lizards. — Srikulnath K, Matsubara K, Uno Y, Nishida C, Olsson M, Matsuda Y Chromosoma (2014)
    9. [9]
      Chromosomal rearrangements and karyotype evolution in carnivores revealed by chromosome painting. — Nie W, Wang J, Su W, Wang D, Tanomtong A, Perelman PL et al. Heredity (2012)
    10. [10]
      High-resolution mapping of interstitial telomeric repeats in Syrian hamster metaphase chromosomes. — Demin S, Pleskach N, Svetlova M, Solovjeva L Cytogenetic and genome research (2011)
    11. [11]
      Chromosomal mapping of rRNA genes, core histone genes and telomeric sequences in Brachidontes puniceus and Brachidontes rodriguezi (Bivalvia, Mytilidae). — Pérez-García C, Guerra-Varela J, Morán P, Pasantes JJ BMC genetics (2010)
    12. [12]
      Construction, characterization, and chromosomal mapping of a fosmid library of the white-cheeked gibbon (Nomascus leucogenys). — Chen L, Ye J, Liu Y, Wang J, Su W, Yang F et al. Genomics, proteomics & bioinformatics (2007)
    13. [13]
      Resolution and evolution of the duck-billed platypus karyotype with an X1Y1X2Y2X3Y3X4Y4X5Y5 male sex chromosome constitution. — Rens W, Grützner F, O'brien PC, Fairclough H, Graves JA, Ferguson-Smith MA Proceedings of the National Academy of Sciences of the United States of America (2004)
    14. [14]
      A high-resolution karyotype of Brassica rapa ssp. pekinensis revealed by pachytene analysis and multicolor fluorescence in situ hybridization. — Koo DH, Plaha P, Lim YP, Hur Y, Bang JW TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik (2004)
    15. [15]
      Female meiosis drives karyotypic evolution in mammals. — Pardo-Manuel de Villena F, Sapienza C Genetics (2001)
    16. [16]
      Identification of crossbred buffalo genotypes and their chromosome segregation patterns. — Harisah M, Azmi TI, Hilmi M, Vidyadaran MK, Bongso TA, Nava ZM et al. Genome (1989)
    17. [17]
      Modes of spontaneous chromosomal mutation and karyotype evolution in ants with reference to the minimum interaction hypothesis. — Imai HT, Taylor RW, Crosland MW, Crozier RH Idengaku zasshi (1988)
    18. [18]
      The chromosome complement of Sorex granarius--the ancestral karyotype of the common shrew (Sorex araneus)? — Wójcik JM, Searle JB Heredity (1988)
    19. [19]
      CHROMPAC III: an improved package for microcomputer-assisted analysis of karyotypes. — Green DM, Myers PZ, Reyna DL The Journal of heredity (1984)
    20. [20]
      Chromosomes of Lemuriformes. V. A comparison of the karyotypes of Cheirogaleus medius and Lemur fulvus fulvus. — Dresser ME, Hamilton AE Cytogenetics and cell genetics (1979)
    21. [21]
      Chromosome homology and evolution of emydid turtles. — Bickham JW, Baker RJ Chromosoma (1976)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG